
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
In honor of Black History Month, Psychiatric Times™ highlights the contributions of Black clinicians to the field of psychiatry, as well as issues that continue to impact this underrepresented community.






